Answers are grounded in this paper and cite their sources.
This cross-sectional study examines atezolizumab as a second-line treatment for malignant urothelial carcinoma, which received accelerated US Food and Drug Administration approval, although the manufacturer’s confirmatory trial did not identify benefits.
No takes yet. Share an insight, caveat, or question.
Ballreich et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: